复方异丙托溴铵联合左沙丁胺醇雾化治疗对COPD患者的治疗效果探究  

Therapeutic effect of compound ipratropium bromide combined with levosalbutamol nebulization on patients with COPD

作　　者：翟沛 郭宏杰[1] 李欣 Zhai Pei;Guo Hong-jie;Li Xin(Department of Respiratory and Critical Care Medicine,The First Affiliated Hospital of Nanyang Medical College,Nanyang 473000,Henan,China)

机构地区：[1]南阳医学高等专科学校第一附属医院呼吸与危重症医学科,河南南阳473000

出　　处：《四川生理科学杂志》2025年第2期298-300,共3页

摘　　要：目的:探讨复方异丙托溴铵联合左沙丁胺醇雾化治疗COPD患者的效果。方法:回顾性收集2021年1月至2023年12月期间本院收治的106例COPD患者的临床资料,根据治疗方案的不同分为对照组52例及观察组54例,对照组采用左沙丁胺醇雾化1mL吸入治疗(2次·d^(-1)),观察组在此基础上联合复方异丙托溴铵2 mL雾化吸入。分别于治疗第1、2、4和7 d天采用呼吸困难评分(Modified medical research council,MMRC)评估呼吸困难症状,治疗2 w后采用肺功能检测仪检测肺功能,包括第一秒用力呼气容积(Forced expiratory Volume in the first second,FEV1)、用力肺活量(Forced vital capacity,FVC)以及FEV1/FVC,采用血气电解质分析仪检测动脉血气,如二氧化碳分压(Partial pressure of carbon dioxide,PaCO_(2))、动脉血氧分压(Arterial partial pressure of oxygen,PaO_(2)),同时统计治疗期间不良反应情况。结果:治疗后第2、4和7 d,观察组MMRC评分均显著低于对照组(P<0.05)。治疗后,观察组FEV1/FVC、FEV1指标值均显著高于对照组(P<0.05)。治疗后,观察组PaO_(2)显著高于对照组(P<0.05);PaCO_(2)显著低于对照组(P<0.05)。两组的不良反应发生率无显著差异(P>0.05)。结论:雾化治疗联合复方异丙托溴铵治疗COPD患者,能显著提升肺功能,减轻呼吸困难症状,改善动脉血气指标,且安全性较高。Objective:To explore the effect of compound ipratropium bromide combined with levosalbutamol nebulization in the treatment of COPD patients.Methods:Retrospectively collect the clinical data of 106 COPD patients admitted to our hospital from January 2021 to December 2023.According to the different treatment plans,they were divided into a control group of 52 patients and an observation group of 54 patients.The control group was treated with inhalation of 1 mL of levosalbutamol nebulization(2 times·d^(-1)),while the observation group was treated with inhalation of 2 mL of compound ipratropium bromide nebulization on this basis.The dyspnea symptoms were evaluated using the Modified Medical Research Council(MMRC)score on days 1,2,4,and 7 of treatment.After 2 weeks of treatment,lung function was measured using a pulmonary function tester,including forced expiratory volume in the first second(FEV1),forced vital capacity(FVC),and FEV1/FVC.Blood gas electrolytes were analyzed using a blood gas analyzer,such as partial pressure of carbon dioxide(PaCO_(2))and arterial partial pressure of oxygen(PaO_(2)).At the same time,adverse reactions during treatment were statistically analyzed.Results:On the 2nd,4th,and 7th day after treatment,the MMRC scores in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the FEV1/FVC and FEV1 index values in the observation group were significantly higher than those in the control group(P<0.05).After treatment,the PaO_(2) in the observation group was significantly higher than that in the control group(P<0.05)and PaCO_(2) was significantly lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of nebulization therapy and compound ipratropium bromide can significantly improve lung function,alleviate dyspnea symptoms,and improve arterial blood gas parameters in patients with COPD,with high safety.

关 键 词：雾化治疗 支气管舒张剂 慢性阻塞性肺疾病 肺功能 血气指标 

分 类 号：R56[医药卫生—呼吸系统]